Peer-review publication, Clinical Infectious Diseases, has noted that Covaxin demonstrates protection against the new COVID-19 variants. Bharat Biotech's Covaxin retained neutralising activity against emerging variants of Coronavirus, as per a new study.

A study published by Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising titres against all key emerging variants tested including B1617 and B117, first identified in India and the UK, respectively. A modest reduction in neutralisation by a factor of 1.95 was observed against the B1617 variant compared to the vaccine variant.

Despite this reduction, neutralising titre levels with B 1617 remain above levels expected to be protective. No difference in neutralisation between B 117 first identified in the UK and vaccine strain was observed. The study was conducted in collaboration with the National Institute of Virology and the Indian Council of Medical Research.